Chih-Wen Su

Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study

Simple Summary Endometrial cancer that returns or spreads after first-line chemotherapy is difficult to treat. The combination of pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy) is a standard second-line option, but clinicians have few tools for estimating the prognosis of individual patients. Usin...